跳转到内容

三陰性乳癌：修订间差异

维基百科，自由的百科全书
以互动方式浏览历史
←上一版本下一版本→
删除的内容 添加的内容
可视化wikitext
第47行： 第47行：
=== 病理组织学 ===
=== 病理组织学 ===
病理组织学的分型有助于预后的判断<ref name=":9">{{Cite journal|title=Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes|author=|url=http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00125480-201509000-00004|last=Bose|first=Shikha|date=2015-09|journal=Advances In Anatomic Pathology|issue=5|doi=10.1097/PAP.0000000000000084|others=|year=|volume=22|page=|pages=306–313|language=en|issn=1072-4109|pmid=}}</ref>和药物试验的筛选<ref name=":1" />。浸润性导管癌是最常见的形态，转移率高，预后较差<ref name=":9" />。采用[[苏木精-伊红染色|苏木素-伊红染色]]可以识别腺样囊性癌<ref name=":1" />，该分型较其它三阴性乳癌增殖率较低，[[预后]]较好<ref>{{Cite journal|title=Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome|author=|url=https://www.clinical-breast-cancer.com/article/S1526-8209(12)00181-4/abstract|last=Colleoni|first=Marco|last2=Viale|first2=Giuseppe|date=2013-02-01|journal=Clinical Breast Cancer|issue=1|doi=10.1016/j.clbc.2012.09.002|others=|year=|volume=13|page=|pages=31–39|language=en|issn=1526-8209|pmid=|last3=Goldhirsch|first3=Aron|last4=Mastropasqua|first4=Mauro G.|last5=Bottiglieri|first5=Luca|last6=Pruneri|first6=Giancarlo|last7=Luini|first7=Alberto|last8=Veronesi|first8=Paolo|last9=Galimberti|first9=Viviana}}</ref>。髓样癌较为罕见，淋巴结很少受累，一般预后良好<ref name=":9" />。化生性的形态亦罕见，多发于老年人，化疗效果差，患者诊断后平均生存期不足一年<ref name=":9" />。
病理组织学的分型有助于预后的判断<ref name=":9">{{Cite journal|title=Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes|author=|url=http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00125480-201509000-00004|last=Bose|first=Shikha|date=2015-09|journal=Advances In Anatomic Pathology|issue=5|doi=10.1097/PAP.0000000000000084|others=|year=|volume=22|page=|pages=306–313|language=en|issn=1072-4109|pmid=}}</ref>和药物试验的筛选<ref name=":1" />。浸润性导管癌是最常见的形态，转移率高，预后较差<ref name=":9" />。采用[[苏木精-伊红染色|苏木素-伊红染色]]可以识别腺样囊性癌<ref name=":1" />，该分型较其它三阴性乳癌增殖率较低，[[预后]]较好<ref>{{Cite journal|title=Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome|author=|url=https://www.clinical-breast-cancer.com/article/S1526-8209(12)00181-4/abstract|last=Colleoni|first=Marco|last2=Viale|first2=Giuseppe|date=2013-02-01|journal=Clinical Breast Cancer|issue=1|doi=10.1016/j.clbc.2012.09.002|others=|year=|volume=13|page=|pages=31–39|language=en|issn=1526-8209|pmid=|last3=Goldhirsch|first3=Aron|last4=Mastropasqua|first4=Mauro G.|last5=Bottiglieri|first5=Luca|last6=Pruneri|first6=Giancarlo|last7=Luini|first7=Alberto|last8=Veronesi|first8=Paolo|last9=Galimberti|first9=Viviana}}</ref>。髓样癌较为罕见，淋巴结很少受累，一般预后良好<ref name=":9" />。化生性的形态亦罕见，多发于老年人，化疗效果差，患者诊断后平均生存期不足一年<ref name=":9" />。

此外，以组织学方法进行染色可以识别[[雄激素受体]]表达阳性者，占三阴性患者数量的四分之一左右<ref>{{Cite journal|title=Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis|author=|url=http://www.oncotarget.com/fulltext/10208|last=Wang|first=Changjun|last2=Pan|first2=Bo|date=2016-07-19|journal=Oncotarget|issue=29|doi=10.18632/oncotarget.10208|others=|year=|volume=7|page=|language=en|issn=1949-2553|pmc=5216811|pmid=27374089|last3=Zhu|first3=Hanjiang|last4=Zhou|first4=Yidong|last5=Mao|first5=Feng|last6=Lin|first6=Yan|last7=Xu|first7=Qianqian|last8=Sun|first8=Qiang}}</ref>。雄激素能促发乳房肿瘤发生，高血浆雄激素水平的女性在绝经后更易患乳腺癌，已证实雄激素可以在动物实验、体外细胞系中诱发癌症，体重指数增加、饮酒和吸烟可能与体内雄激素水平上升有关<ref name=":10">{{Cite journal|title=Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype|author=|url=http://link.springer.com/10.1245/s10434-013-3260-7|last=McGhan|first=Lee J.|last2=McCullough|first2=Ann E.|date=2014-02|journal=Annals of Surgical Oncology|issue=2|doi=10.1245/s10434-013-3260-7|others=|year=|volume=21|page=|pages=361–367|language=en|issn=1068-9265|pmid=|last3=Protheroe|first3=Cheryl A.|last4=Dueck|first4=Amylou C.|last5=Lee|first5=James J.|last6=Nunez-Nateras|first6=Rafael|last7=Castle|first7=Erik P.|last8=Gray|first8=Richard J.|last9=Wasif|first9=Nabil}}</ref>。雄激素受体表达阳性的三阴性乳癌患者总生存率较高，预后较好<ref name=":10" />。使用雄激素抑制剂[[靶向治疗]]三阴性乳腺癌已经进入临床试验阶段<ref>{{Cite journal|title=Role of the Androgen Receptor in Triple-Negative Breast Cancer|author=|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221599/|last=Rampurwala|first=Murtuza|last2=Wisinski|first2=Kari B.|date=2016-03|journal=Clinical advances in hematology & oncology : H&O|issue=3|doi=|others=|year=|volume=14|page=|pages=186–193|issn=1543-0790|pmc=5221599|pmid=27058032|last3=O’Regan|first3=Ruth}}</ref>。

=== 分子特征 ===
三阴性主要为临床用语，基底样为cDNA微阵列定义的分子表型<ref>{{Cite web|url=https://www.cancernetwork.com/triple-negative-breast-cancer/understanding-and-treating-triple-negative-breast-cancer|title=Understanding and Treating Triple-Negative Breast Cancer|accessdate=2019-05-15|author=Anders, C. K.; Carey, L. A.|date=2008-10-01|publisher=MultiMedia Healthcare, LLC}}</ref>。基底样和三阴性两个术语被交替使用但有所差异，基底样分型占据三阴性乳癌的70-80%，基底样基因表达可能是三阴性乳癌患者之间的主要生物学差异<ref>{{Cite journal|title=Molecular characterization of basal-like and non-basal-like triple-negative breast cancer|author=|url=https://www.ncbi.nlm.nih.gov/pubmed/23404817|last=Prat|first=Aleix|last2=Adamo|first2=Barbara|date=2013|journal=The Oncologist|issue=2|doi=10.1634/theoncologist.2012-0397|others=|year=|volume=18|page=|pages=123–133|issn=1549-490X|pmc=3579595|pmid=23404817|last3=Cheang|first3=Maggie C. U.|last4=Anders|first4=Carey K.|last5=Carey|first5=Lisa A.|last6=Perou|first6=Charles M.}}</ref>。依照基因表达图谱，三阴性乳癌大致可以分为基底样、非基底样、Claudin-low型<ref>{{Cite journal|title=Claudins在乳腺癌中的研究进展|author=钱松颖; 李建一; 张文海|url=http://www.cnki.com.cn/Article/CJFDTotal-ZPWL201602042.htm|journal=中国普外基础与临床杂志|issue=2|doi=|others=|year=2016|volume=|page=|pmid=}}</ref>或基底样免疫激活、基底样免疫抑制、雄激素受体表达、间叶细胞等分型<ref>{{Cite journal|title=Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer|author=|url=http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-14-0432|last=Burstein|first=M. D.|last2=Tsimelzon|first2=A.|date=2015-04-01|journal=Clinical Cancer Research|issue=7|doi=10.1158/1078-0432.CCR-14-0432|others=|year=|volume=21|page=|pages=1688–1698|language=en|issn=1078-0432|pmc=4362882|pmid=25208879|last3=Poage|first3=G. M.|last4=Covington|first4=K. R.|last5=Contreras|first5=A.|last6=Fuqua|first6=S. A. W.|last7=Savage|first7=M. I.|last8=Osborne|first8=C. K.|last9=Hilsenbeck|first9=S. G.}}</ref>，以及其它的分类方法<ref>{{Cite journal|title=Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response|url=https://doi.org/10.1186/s13058-015-0550-y|last=Jézéquel|first=Pascal|last2=Loussouarn|first2=Delphine|date=2015-03-20|journal=Breast Cancer Research|issue=1|doi=10.1186/s13058-015-0550-y|volume=17|pages=43|issn=1465-542X|last3=Guérin-Charbonnel|first3=Catherine|last4=Campion|first4=Loïc|last5=Vanier|first5=Antoine|last6=Gouraud|first6=Wilfried|last7=Lasla|first7=Hamza|last8=Guette|first8=Catherine|last9=Valo|first9=Isabelle}}</ref>。不同分型间显示出的免疫调节、雄激素信号、生长因子通路等差异为药物研发提供了靶点<ref>{{Cite journal|title=Subtyping of triple-negative breast cancer: Implications for therapy|author=|url=https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.28914|last=Abramson|first=Vandana G.|last2=Lehmann|first2=Brian D.|date=2015|journal=Cancer|issue=1|doi=10.1002/cncr.28914|others=|year=|volume=121|page=|pages=8–16|language=en|issn=1097-0142|pmc=4270831|pmid=25043972|last3=Ballinger|first3=Tarah J.|last4=Pietenpol|first4=Jennifer A.}}</ref>。


== 参考文献 ==
== 参考文献 ==

2019年5月15日 (三) 13:48的版本

三陰性乳癌
症状组织细胞突变率高、肿瘤分级高、存在坏死和炎症浸润，不同亚型有所差异[1]
类型乳癌、triple-negative breast neoplasm[*]
风险因素
診斷方法免疫组化[3]
治療外科学
放射線療法
化学疗法
靶向治疗
预后依照分型有所差异，多数较差
患病率10-20%的乳癌病例
分类和外部资源
醫學專科肿瘤学
[编辑此条目的维基数据]

三陰性乳癌（英語：Triple-negative breast cancer，缩写为TNBC），也称三阴性乳腺癌，是指缺乏雌激素受体（英语：Estrogen receptor）（ESr或Er）、孕酮受体（Pr）表达与缺乏表皮生长因子受体-2（HER）过表达或者增殖的乳癌[1]，临床上一般通过免疫组化确定[3]。这三个特征常见于其它乳癌中，却少见于此分型中[1]，如激素治疗等在内的常见乳癌治疗方案往往针对这三类受体，因而对三阴性乳癌患者一般无效[4]。目前主要采取化疗对该癌症包括转移期在内各个阶段进行治疗[5]。虽然化疗可在病理学意义上完全消除许多三阴性乳腺癌患者的肿瘤[1]，但因复发率较高，对患者预期生存时间改善不大，这一矛盾现象也被称为“三阴性悖论”[6][7]。与其它药物进行联合治疗已经被临床试验证实有效[8]。在美国，超50%的可选择手术的患者选择了乳房切除术[4]。

三阴性作为一种侵袭性表型，主要表现为基底样或正常乳腺样肿瘤[3]，90%为单灶性浸润性导管癌[3]。该型癌症易发转移，复发较多且较早，缺乏获批准（英语：Approved drug）的靶向治疗方法[4]。该型癌症具有高度异质性，因此可能并非单一疾病，而是不同疾病之集合[9]，依据组织学、细胞起源、突变、转移潜能、疾病进展、治疗反应和临床结果等，还可以分出可以采取不同治疗策略的亚型[1][10]，如针对BRCA突变的患者已经出现PARP抑制剂（英语：PARP inhibitor）等靶向治疗药物[11][12][13]。不同亚型对药物的反应也不同，如病人无BRCA1/2突变或有肿瘤浸润淋巴细胞浓度增加，则已有试验证实卡铂联合紫杉醇进行新辅助（英语：Neoadjuvant therapy）化疗效果更好[14][15]。对于不同亚型的预后也会有所差异，诺丁汉预后指数可以帮助进行预后判断，但需要更激进治疗者除外[16]。

风险因子

该症的风险因子的研究仍然受限于对三阴性乳癌的分型研究与人口统计数据[17]。其在美国乳癌病例中占15%左右[4]，在亚洲的乳癌病例中占10-17%[10]。多发于年轻女性，可能与BRCA1基因突变相关[2]。非洲裔、西班牙裔等群体在内特定族裔呈现高发，可能与较差社会经济地位相关[2]。肥胖亦为该疾病的风险因子，身高体重指数较高者易患病[18]。对于不到40岁的女性群体，长期口服避孕药物是否促进该型癌症发生，目前试验数据的结果尚存矛盾[17]。

分型及临床意义

在美国，免疫组学结果显示激素受体1%阳性以下的乳癌患者视为三阴性患者，过去视为三阴性的对1-10%的阳性表达患者进行激素治疗仍然显示有效[19]，但针对三阴性分型的靶向治疗药物是否适用与此类病人难以判断[1]。

依照病理组织学、基因组学等，三阴性乳腺癌可以分为若干种分型[1][10]。

BRCA基因

BRCA基因突变携带者易感于乳腺癌、卵巢癌、胰腺癌和前列腺癌等多种癌症[20]，携带该突变是三阴性乳癌的风险因子之一。波兰和澳大利亚的研究显示，BRCA突变者占三阴性乳癌群体的10%左右[21]。现有试验表明，BRCA1突变群体采取添加顺铂的新辅助（英语：Neoadjuvant therapy）化疗之效果较其他群体更优[22][23]，双侧乳房摘除[24]和卵巢摘除[25]对BRCA1基因突变效果亦较好。

超八成的三阴性乳癌表达突变p53蛋白，阻碍正常的DNA修复，突变之p53蛋白被视为三阴性乳癌的病因[26]。以PARP抑制剂（英语：PARP inhibitor）诱导DNA单链断裂，以抑制癌细胞DNA的修复，可清除肿瘤的发生，而对于有修复能力的普通细胞而无杀伤性[26]。BRCA1/2介导了同源重组[27]，对BRCA1/2突变携带者使用PARP抑制剂，可以致使肿瘤细胞死亡，目前以合成致死性的理论解释之，即正常BRCA和PARP同时缺失可以致死[28]相关药物已经进入临床试验阶段并针对BRCA突变者有较好疗效[27]。

病理组织学

病理组织学的分型有助于预后的判断[29]和药物试验的筛选[1]。浸润性导管癌是最常见的形态，转移率高，预后较差[29]。采用苏木素-伊红染色可以识别腺样囊性癌[1]，该分型较其它三阴性乳癌增殖率较低，预后较好[30]。髓样癌较为罕见，淋巴结很少受累，一般预后良好[29]。化生性的形态亦罕见，多发于老年人，化疗效果差，患者诊断后平均生存期不足一年[29]。

此外，以组织学方法进行染色可以识别雄激素受体表达阳性者，占三阴性患者数量的四分之一左右[31]。雄激素能促发乳房肿瘤发生，高血浆雄激素水平的女性在绝经后更易患乳腺癌，已证实雄激素可以在动物实验、体外细胞系中诱发癌症，体重指数增加、饮酒和吸烟可能与体内雄激素水平上升有关[32]。雄激素受体表达阳性的三阴性乳癌患者总生存率较高，预后较好[32]。使用雄激素抑制剂靶向治疗三阴性乳腺癌已经进入临床试验阶段[33]。

分子特征

三阴性主要为临床用语，基底样为cDNA微阵列定义的分子表型[34]。基底样和三阴性两个术语被交替使用但有所差异，基底样分型占据三阴性乳癌的70-80%，基底样基因表达可能是三阴性乳癌患者之间的主要生物学差异[35]。依照基因表达图谱，三阴性乳癌大致可以分为基底样、非基底样、Claudin-low型[36]或基底样免疫激活、基底样免疫抑制、雄激素受体表达、间叶细胞等分型[37]，以及其它的分类方法[38]。不同分型间显示出的免疫调节、雄激素信号、生长因子通路等差异为药物研发提供了靶点[39]。

参考文献

  1. ^ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Minckwitz, Gunter von; Tutt, Andrew; Liedtke, Cornelia; Denkert, Carsten. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. The Lancet. 2017-06-17, 389 (10087): 2430–2442. ISSN 0140-6736. PMID 27939063. doi:10.1016/S0140-6736(16)32454-0 （英语）. 
  2. ^ 2.0 2.1 2.2 Gianni, Luca; Hudis, Clifford A. Triple-Negative Breast Cancer: An Unmet Medical Need. The Oncologist. 2011-01-01, 16 (Supplement 1): 1–11. ISSN 1083-7159. PMID 21278435. doi:10.1634/theoncologist.2011-S1-01 （英语）. 
  3. ^ 3.0 3.1 3.2 3.3 Kumar, Pankaj; Aggarwal, Rupali. An overview of triple-negative breast cancer. Archives of Gynecology and Obstetrics. 2016-02, 293 (2): 247–269. ISSN 0932-0067. doi:10.1007/s00404-015-3859-y （英语）. 
  4. ^ 4.0 4.1 4.2 4.3 Sharma, Priyanka. Biology and Management of Patients With Triple-Negative Breast Cancer. The Oncologist. 2016-09, 21 (9): 1050–1062. ISSN 1549-490X. PMC 5016071 可免费查阅. PMID 27401886. doi:10.1634/theoncologist.2016-0067. 
  5. ^ Gadi, Vijayakrishna K.; Davidson, Nancy E. Practical Approach to Triple-Negative Breast Cancer. Journal of Oncology Practice. 2017-05-01, 13 (5): 293–300. ISSN 1554-7477. doi:10.1200/JOP.2017.022632. 
  6. ^ Perou, Charles M.; Graham, Mark L.; Sartor, Carolyn I.; Ollila, David W.; Collichio, Frances; Moore, Dominic T.; Gatti, Lisa; Sawyer, Lynda; Dees, E. Claire. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clinical Cancer Research. 2007-04-15, 13 (8): 2329–2334. ISSN 1078-0432. PMID 17438091. doi:10.1158/1078-0432.CCR-06-1109 （英语）. 
  7. ^ Perou, Charles M.; Graham, Mark L.; Sartor, Carolyn I.; Ollila, David W.; Collichio, Frances; Moore, Dominic T.; Gatti, Lisa; Sawyer, Lynda; Dees, E. Claire. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clinical Cancer Research. 2007-04-15, 13 (8): 2329–2334. ISSN 1078-0432. PMID 17438091. doi:10.1158/1078-0432.CCR-06-1109 （英语）. 
  8. ^ Chalakur-Ramireddy, Naveen K.R.; Pakala, Suresh B. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. Bioscience Reports. 2018-01-30, 38 (1). ISSN 0144-8463. PMC 5789156 可免费查阅. PMID 29298879. doi:10.1042/BSR20171357. 
  9. ^ Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S. Triple-Negative Breast Cancer. New England Journal of Medicine. 2010, 363 (20): 1938–1948. doi:10.1056/Nejmra1001389. 
  10. ^ 10.0 10.1 10.2 Wang, Chao; Kar, Shreya; Lai, Xianning; Cai, Wanpei; Arfuso, Frank; Sethi, Gautam; Lobie, Peter E.; Goh, Boon C.; Lim, Lina H.K. Triple negative breast cancer in Asia: An insider’s view. Cancer Treatment Reviews. 2018-01, 62: 29–38. doi:10.1016/j.ctrv.2017.10.014 （英语）. 
  11. ^ Robson, Mark; Im, Seock-Ah; Senkus, Elżbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Li, Wei; Tung, Nadine. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine. 2017-08-10, 377 (6): 523–533. ISSN 0028-4793. PMID 28578601. doi:10.1056/NEJMoa1706450. 
  12. ^ 佩妮. PARP抑制剂在三阴性乳腺癌中的应用. 药渡. 2018-03-23 [2019-05-14] –通过新浪医药. 
  13. ^ Litton, Jennifer; Hannah, Alison; Blum, Joanne; Tudor, Iulia; Markova, Denka; Miguel, Martin; Gonçalves, Anthony; Hurvitz, Sara A.; Ettl, Johannes. A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age. The Breast. 2018-10-01, 41: S12. ISSN 0960-9776. doi:10.1016/j.breast.2018.08.034 （英语）. 
  14. ^ 钱多乐. 三阴性乳腺癌新辅助化疗标准 柳叶刀揭示卡铂能带来什么？. 医脉通肿瘤科. 2018-03-05 [2019-05-15] –通过健康界. 
  15. ^ Geyer, Charles E.; Liu, Xuan; Symmans, W. Fraser; Rastogi, Priya; Filho, Otto Metzger; Lorenzo, Jose J. Ponce; McIntyre, Kristi; Wolmark, Norman; Sullivan, Danielle. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. The Lancet Oncology. 2018-04-01, 19 (4): 497–509. ISSN 1470-2045. PMID 29501363. doi:10.1016/S1470-2045(18)30111-6 （英语）. 
  16. ^ Albergaria, A.; Ricardo, S.; Milanezi, F.; Carneiro, V. T.; Amendoeira, I.; Vieira, D.; Cameselle-Teijeiro, J.; Schmitt, F. Nottingham Prognostic Index in Triple-Negative Breast Cancer: A reliable prognostic tool?. BMC Cancer. 2011, 11: 299. PMC 3151231 可免费查阅. PMID 21762477. doi:10.1186/1471-2407-11-299. 
  17. ^ 17.0 17.1 Boyle, P. Triple-negative breast cancer: epidemiological considerations and recommendations. Annals of Oncology. 2012-08-01, 23 (suppl_6): vi7–vi12. ISSN 0923-7534. doi:10.1093/annonc/mds187 （英语）. 
  18. ^ Pierobon, Mariaelena; Frankenfeld, Cara L. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Research and Treatment. 2013-01-01, 137 (1): 307–314. ISSN 1573-7217. doi:10.1007/s10549-012-2339-3 （英语）. 
  19. ^ Hammond, M. Elizabeth H.; Hayes, Daniel F.; Dowsett, Mitch; Allred, D. Craig; Hagerty, Karen L.; Badve, Sunil; Fitzgibbons, Patrick L.; Francis, Glenn; Goldstein, Neil S. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology. 2010-06, 28 (16): 2784–2795. ISSN 0732-183X. PMC 2881855 可免费查阅. PMID 20404251. doi:10.1200/JCO.2009.25.6529 （英语）. 
  20. ^ Pharoah, Paul D. P.; Goode, Ellen L.; Gayther, Simon A.; Jimenez-Linan, Mercedes; Alsop, Jennifer; Tyrer, Jonathan P.; Fridley, Brooke L.; Cunningham, Julie M.; Ramus, Susan J. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Human Molecular Genetics. 2014-09-01, 23 (17): 4703–4709. ISSN 0964-6906. doi:10.1093/hmg/ddu172 （英语）. 
  21. ^ Wong-Brown, Michelle W.; Meldrum, Cliff J.; Carpenter, Jane E.; Clarke, Christine L.; Narod, Steven A.; Jakubowska, Anna; Rudnicka, Helena; Lubinski, Jan; Scott, Rodney J. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Research and Treatment. 2015-02-01, 150 (1): 71–80. ISSN 1573-7217. doi:10.1007/s10549-015-3293-7 （英语）. 
  22. ^ Rennert, Gad; Bisland-Naggan, Shantih; Barnett-Griness, Ofra; Bar-Joseph, Naomi; Zhang, Shiyu; Rennert, Hedy S.; Narod, Steven A. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. The New England Journal of Medicine. 2007-07-12, 357 (2): 115–123. ISSN 1533-4406. PMID 17625123. doi:10.1056/NEJMoa070608. 
  23. ^ Byrski, Tomasz; Gronwald, Jacek; Huzarski, Tomasz; Grzybowska, Ewa; Budryk, Magdalena; Stawicka, Malgorzata; Mierzwa, Tomasz; Szwiec, Marek; Wisniowski, Rafal. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010-01-20, 28 (3): 375–379. ISSN 1527-7755. PMID 20008645. doi:10.1200/JCO.2008.20.7019. 
  24. ^ Narod, Steven A.; Sun, Ping; Rosen, Barry; Foulkes, William D.; Eisen, Andrea; Kim-Sing, Charmaine; Tung, Nadine; Snyder, Carrie; Lynch, Henry T. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014-02-11, 348: g226. ISSN 1756-1833. PMC 3921438 可免费查阅. PMID 24519767. doi:10.1136/bmj.g226 （英语）. 
  25. ^ Huzarski, Tomasz; Byrski, Tomasz; Gronwald, Jacek; Górski, Bohdan; Domagala, Pawel; Cybulski, Cezary; Oszurek, Oleg; Szwiec, Marek; Gugala, Karol. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013-09-10, 31 (26): 3191–3196. ISSN 1527-7755. PMID 23940229. doi:10.1200/JCO.2012.45.3571. 
  26. ^ 26.0 26.1 Bargonetti, Jill; Hendrickson, Ronald C.; Philip, John; Hu, Wenwei; Zhao, Yuhan; Di, Lia; Xiao, Gu; Polotskaia, Alla; Qiu, Wei-Gang. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. npj Breast Cancer. 2017-01-19, 3 (1): 1. ISSN 2374-4677. doi:10.1038/s41523-016-0001-7 （英语）. 
  27. ^ 27.0 27.1 Lord, Christopher J.; Tutt, Andrew N.J.; Ashworth, Alan. Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors. Annual Review of Medicine. 2015, 66 (1): 455–470. PMID 25341009. doi:10.1146/annurev-med-050913-022545. 
  28. ^ Helleday, Thomas. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Molecular Oncology. 2011-08, 5 (4): 387–393. ISSN 1878-0261. PMC 5528309 可免费查阅. PMID 21821475. doi:10.1016/j.molonc.2011.07.001. 
  29. ^ 29.0 29.1 29.2 29.3 Bose, Shikha. Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes. Advances In Anatomic Pathology. 2015-09, 22 (5): 306–313. ISSN 1072-4109. doi:10.1097/PAP.0000000000000084 （英语）. 
  30. ^ Colleoni, Marco; Viale, Giuseppe; Goldhirsch, Aron; Mastropasqua, Mauro G.; Bottiglieri, Luca; Pruneri, Giancarlo; Luini, Alberto; Veronesi, Paolo; Galimberti, Viviana. Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. Clinical Breast Cancer. 2013-02-01, 13 (1): 31–39. ISSN 1526-8209. doi:10.1016/j.clbc.2012.09.002 （英语）. 
  31. ^ Wang, Changjun; Pan, Bo; Zhu, Hanjiang; Zhou, Yidong; Mao, Feng; Lin, Yan; Xu, Qianqian; Sun, Qiang. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. Oncotarget. 2016-07-19, 7 (29). ISSN 1949-2553. PMC 5216811 可免费查阅. PMID 27374089. doi:10.18632/oncotarget.10208 （英语）. 
  32. ^ 32.0 32.1 McGhan, Lee J.; McCullough, Ann E.; Protheroe, Cheryl A.; Dueck, Amylou C.; Lee, James J.; Nunez-Nateras, Rafael; Castle, Erik P.; Gray, Richard J.; Wasif, Nabil. Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype. Annals of Surgical Oncology. 2014-02, 21 (2): 361–367. ISSN 1068-9265. doi:10.1245/s10434-013-3260-7 （英语）. 
  33. ^ Rampurwala, Murtuza; Wisinski, Kari B.; O’Regan, Ruth. Role of the Androgen Receptor in Triple-Negative Breast Cancer. Clinical advances in hematology & oncology : H&O. 2016-03, 14 (3): 186–193. ISSN 1543-0790. PMC 5221599 可免费查阅. PMID 27058032. 
  34. ^ Anders, C. K.; Carey, L. A. Understanding and Treating Triple-Negative Breast Cancer. MultiMedia Healthcare, LLC. 2008-10-01 [2019-05-15]. 
  35. ^ Prat, Aleix; Adamo, Barbara; Cheang, Maggie C. U.; Anders, Carey K.; Carey, Lisa A.; Perou, Charles M. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The Oncologist. 2013, 18 (2): 123–133. ISSN 1549-490X. PMC 3579595 可免费查阅. PMID 23404817. doi:10.1634/theoncologist.2012-0397. 
  36. ^ 钱松颖; 李建一; 张文海. Claudins在乳腺癌中的研究进展. 中国普外基础与临床杂志. 2016, (2). 
  37. ^ Burstein, M. D.; Tsimelzon, A.; Poage, G. M.; Covington, K. R.; Contreras, A.; Fuqua, S. A. W.; Savage, M. I.; Osborne, C. K.; Hilsenbeck, S. G. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research. 2015-04-01, 21 (7): 1688–1698. ISSN 1078-0432. PMC 4362882 可免费查阅. PMID 25208879. doi:10.1158/1078-0432.CCR-14-0432 （英语）. 
  38. ^ Jézéquel, Pascal; Loussouarn, Delphine; Guérin-Charbonnel, Catherine; Campion, Loïc; Vanier, Antoine; Gouraud, Wilfried; Lasla, Hamza; Guette, Catherine; Valo, Isabelle. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Research. 2015-03-20, 17 (1): 43. ISSN 1465-542X. doi:10.1186/s13058-015-0550-y. 
  39. ^ Abramson, Vandana G.; Lehmann, Brian D.; Ballinger, Tarah J.; Pietenpol, Jennifer A. Subtyping of triple-negative breast cancer: Implications for therapy. Cancer. 2015, 121 (1): 8–16. ISSN 1097-0142. PMC 4270831 可免费查阅. PMID 25043972. doi:10.1002/cncr.28914 （英语）. 
取自“https://zh.wikipedia.org/w/index.php?title=三陰性乳癌&oldid=54428402”